Top

Published in:

01-09-2010 | Brief Report

Adjuvant chemotherapy in young women with breast cancer

Author: Álvaro Rodríguez-Lescure

Published in: Breast Cancer Research and Treatment | Special Issue 1/2010

Excerpt

Adjuvant chemotherapy in operable breast cancer is a field that has not stopped evolving since 1976 when Bonadonna et al. [1] observed a reduction in the risk of recurrence of breast cancer in women with positive axillary lymph nodes after having received a combination of cyclophosphamide, methotrexate, and 5-fluorouracil. Later, anthracyclines and taxanes were incorporated into polychemotherapy regimens, and further improvements in terms of disease free-survival (DFS), overall survival (OS), and loco-regional control were obtained [2, 3]. Today, many different combinations of cytotoxic agents exist, but because of the lack of specific markers for response to individual chemotherapeutic agents, there are no clear indications to prefer one particular regimen over another in the setting of adjuvant chemotherapy [4]. …

Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294(8):405–410CrossRefPubMed

Levine MN, Whelan T (2006) Adjuvant chemotherapy for breast cancer—30 years later. N Engl J Med 355(18):1920–1922CrossRefPubMed

López-Tarruella S, Martín M (2009) Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 11(2):204CrossRefPubMed

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329CrossRefPubMed

Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53CrossRefPubMed

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330CrossRefPubMed

Bharat A, Aft RL, Gao F, Margenthaler JA (2009) Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol 100(3):248–251CrossRefPubMed

Zhou P, Gautam S, Recht A (2007) Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 101(1):51–57CrossRefPubMed

10.

Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL et al (2001) Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 92(10):2523–2528CrossRefPubMed

11.

Peppercorn J (2009) Breast cancer in women under 40. Oncology 23(6):465–474PubMed

12.

Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320(7233):474–478CrossRefPubMed

13.

Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL et al (2009) Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734–744PubMed

14.

Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J et al (2001) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr (30):44–51

15.

Hickey M, Peate M, Saunders CM, Friedlander M (2009) Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 15(3):323–339CrossRefPubMed

16.

Lee S, Kil WJ, Chun M, Jung YS, Kang SY, Kang SH et al (2009) Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 16(1):98–103CrossRefPubMed

17.

Chabbert-Buffet N, Uzan C, Gligorov J, Delaloge S, Rouzier R, Uzan S (2010) Pregnancy after breast cancer: a need for global patient care, starting before adjuvant therapy. Surg Oncol 19(1):47–55CrossRef

18.

Cruz MR, Prestes JC, Gimenes DL, Fanelli MF (2010) Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review. Fertil Steril 94(1):138–143CrossRefPubMed

Title: Adjuvant chemotherapy in young women with breast cancer
Author: Álvaro Rodríguez-Lescure
Publication date: 01-09-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue Special Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1039-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Epidemiology of breast cancer in young women

Adjuvant endocrine therapy in premenopausal women with breast cancer

Breast cancer in young women

Neoadjuvant treatment in young women with breast cancer

Breast cancer in young women

Quality of life during treatment in young women with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer